Lynn A. Tetrault

Director Lynn A. Tetrault sold 37,000 RYTM shares at $100.32 (2026-06-22) via pre-arranged 10b5-1 plan; retains 7,000 shares post-sale.

Lynn A. Tetrault, a director, executed a scheduled sale of 37,000 shares for $3,711,895.50 under a 10b5-1 trading plan adopted on 2025-12-15. The sale reduced his non-derivative holdings from 44,000 shares to 7,000 shares. Prior sales at RYTM have shown a pattern of negative 30-day returns (ranging from -2.2% to -5.2%) followed by positive 90-day performance (ranging from +13.5% to +17.7%). The stock is trading at $107.55, down -12.0% from its 52-week high of $122.20, though it has gained +22.4% over the past 30 days and +31.3% over 90 days. The company generated $60,112,000.00 in revenue last quarter but remains unprofitable with a net loss of $-55,639,000.00, though annual revenue growth reached +45.8%. Because this sale is pre-arranged and not discretionary, it reflects scheduling compliance rather than discretionary timing decisions.

Director TETRAULT LYNN A. buys 7,000 shares of NEO at $8.14; stock down 56.7% from 52-week high, firm unprofitable, but 5 other insiders bought within 14 days

TETRAULT LYNN A., a director, initiated a position of 7,000 shares at $8.14 on 2025-05-09, representing his first purchase in this ticker following zero prior holdings. The transaction occurs against a sharply depressed valuation context: the stock trades at $8.05 currently, -56.7% from its 52-week high of $18.61, and -40.2% over 90 days. NEOGENOMICS is unprofitable (net income $-25.9M in the latest quarter) despite positive annual revenue growth of +11.6%. The purchase is part of a cluster pattern: 5 other insiders also bought within the past 14 days, suggesting coordinated or independent confidence-building activity at the current price level. His cross-ticker track record shows 4 prior open-market sells with a 0.00% well-timed rate (none of those sales preceded stock declines), which provides limited directional guidance for this new buy.

Director Tetrault sold 20,700 shares (87.3% of holdings) for $1.0M at $49.71 avg in 4 transactions

TETRAULT LYNN A., a director at Rhythm Pharmaceuticals, executed 4 separate sales totaling 20,700 shares for $1,028,991.13 on September 9–10, 2024, reducing his shareholding from 23,700 shares to 3,000 shares—a reduction of 87.3% relative to pre-transaction holdings. The sales occurred at prices ranging from $49.05 to $50.60, generating a blended average price of $49.71, marginally below the current price of $49.31 and within the 52-week range of $21.39–$53.89 (approximately 8.5% below the 52-week high). Rhythm Pharmaceuticals is a growing but unprofitable company with recent quarterly revenue of $29,078,000.00 and negative net income of $-32,261,000.00, though annual revenue growth stands at +227.6% year-over-year. The material reduction in director ownership warrants attention given the magnitude of the liquidation and the company's current operating losses, though the absence of additional context regarding timing, scheduled trading plans, or coordinated activity limits interpretation.